Answers are grounded in this paper and cite their sources.
Y-chromosomal abnormalities are established causes of severe spermatogenic impairment, but regional deletions do not establish the contribution of each affected gene. This critical narrative review examines human genetic observations, expression studies, experimental models, and clinical guidance concerning DDX3Y, an RNA helicase, and USP9Y, a ubiquitin-specific protease, within the azoospermia factor a (AZFa) region. Evidence is interpreted by lesion type, reproductive phenotype, developmental stage, and experimental endpoint, without meta-analysis. Rare DDX3Y loss-of-function variants associated with non-obstructive azoospermia, protein localization in premeiotic germ cells, and experimental complementation converge on a major role in early human germ-cell development. However, the small, clinically selected carrier series do not establish penetrance across variant classes. In contrast, isolated USP9Y deletions have been naturally transmitted, and complete gene loss has been documented with preserved sperm production. A reported USP9Y-deleting, DDX3Y-retaining partial AZFa deletion coexisted with congenital bilateral absence of the vas deferens and intact spermatogenesis, illustrating the need to distinguish obstruction from production failure. Mouse fertility and somatic-cell paralog buffering cannot establish functional substitution in human germ cells. Overall, the gene-specific evidence is stronger for DDX3Y than for USP9Y. Clinical interpretation should integrate deletion boundaries, variant-level evidence, and phenotypic assessment. Selection, language, and publication bias remain possible in this non-systematic synthesis. Experimental rescue of early germ-cell development does not establish a clinically available fertility treatment.
No takes yet. Share an insight, caveat, or question.
Marwa Abbas Kubba (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: